ClinicalTrials.gg
CompletedNCT05137236Updated Jul 17, 2025Results posted

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

A Phase 2 interventional study of mRNA-1283 and mRNA-1283.211 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 17 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-17.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in COVID-19 by Moderna, Inc. — 3 open to participants now, 6 under way, none of them phase 3. COVID-19 · Moderna, Inc..

Enrollment
15th of 22
540 · median 988
Started
2021
with 7 others
Phase 2
5 of 34
1 open now
Registered
11th of 34
by date

Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 15th largest by enrollment of the 22 interventional ones that give a count, is one of 8 that started in 2021, is one of 5 in phase 2, and was the 11th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 34 studies in COVID-19 by Moderna, Inc. are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in COVID-19 by Moderna, Inc., or all of them as a file.
02

Study summary

The main goal of Part A of this study is to assess the safety, reactogenicity, and immunogenicity of the study vaccine candidates. The main goal of Part B of this study is to assess the safety, reactogenicity, and immunogenicity of the mRNA-1283.529 booster vaccine candidate.

Read the detailed description

Part A of this study will assess whether a single dose of mRNA-1283 at three different dose levels or mRNA-1283.211 at two different dose levels will boost antibody responses to the Wuhan-Hu-1 (ancestral strain of SARS-CoV-2) virus, and to the B.1.351 variant, and potentially other SARS-CoV-2 variants, and it will also be used to select a dose for subsequent clinical evaluation. The study will include an active comparator group of participants who will receive mRNA-1273.

Participants in Part A who received the primary series of mRNA-1273 with appropriate documentation at least 6 months prior will be randomized 1:1:1:1:1:1 to receive a single boost of mRNA-1283 at one of three dose levels, a single boost of mRNA-1283.211 at one of two dose levels, or a single dose of the active comparator, mRNA-1273.

Part B of this study will assess whether a single dose of mRNA-1283.529 at two different dose levels as the second booster after a first booster of mRNA- 1273, at least 3 months prior, will boost antibody response to the ancestral strain of the SARS-CoV-2 virus, the B.1.1.529 variant, and potentially other SARS-CoV-2 variants, and inform dose selection for mRNA-1283.529 booster vaccine candidate for subsequent clinical evaluation.

Participants in Part B who received the primary series of mRNA 1273 and who received a first booster dose of mRNA-1273 at least 3 months prior will be enrolled in a 1:1 ratio to receive a single boost of mRNA 1283.529 at one of two dose levels.

03

Conditions studied

  • SARS-CoV-2

Browse trials for

Keywords

  • mRNA-1273
  • mRNA-1273 vaccine
  • SARS-CoV-2
  • SARS-CoV-2 Vaccine
  • Coronavirus
  • Virus Diseases
  • Messenger RNA
  • COVID-19
  • COVID-19 Vaccine
  • Moderna
04

In context

COVID-19 Reclassified

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

This study's enrollment of 540 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants of nonchildbearing potential may be enrolled in the study. Nonchildbearing potential is defined as bilateral tubal ligation >1 year prior to screening, bilateral oophorectomy, hysterectomy, or menopause.
  • Female participants of may be enrolled in the study if the participant has a negative pregnancy test on the day of vaccination (Day 1), practiced adequate or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreed to continue adequate contraception through 3 months following the last vaccine administration, and not currently breastfeeding.
  • Participant must have received their second dose of the mRNA-1273 primary series at least 6 months prior to screening and enrollment (Part A) or have received the mRNA-1273 series and an mRNA-1273 booster dose at least 3 months prior to screening and enrollment (Part B).

Exclusion criteria

Exclusion Criteria:

  • Had significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 14 days, defined by the US Centers for Disease Control and Prevention (CDC) as a close contact of someone who has COVID-19.
  • Is acutely ill or febrile (temperature ≥38.0 degree Celsius [°C]/100.4 degree Fahrenheit [°F]) less than 72 hours prior to or at the screening visit or Day 1.
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • Has received systemic or immune-modifying drugs for >14 days in total within 6 months prior to screening (for ≥10 milligrams [mg]/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
  • Has received or plans to receive any licensed vaccine ≤28 days prior to the injection (Day 1) or plans to receive a licensed vaccine within 28 days before or after the study injection, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study vaccine.
  • Has received systemic immunoglobulins or blood products within 3 months prior to the screening visit, or plans to receive these during the study.
  • Has donated ≥ 450 milliliters (mL) of blood products within 28 days prior to the screening visit or plans to donate blood products during the study.
  • Plans to participate in an interventional clinical trial of an vaccine or drug while participating in this study.

Note: Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
540 participants (actual)

Study arms

  • Experimental
    Part A: mRNA-1283 Dose Level 1

    Participants will receive single intramuscular (IM) injection of mRNA-1283 at Dose Level 1 on Day 1.

    Biological: mRNA-1283

  • Experimental
    Part A: mRNA-1283 Dose Level 2

    Participants will receive single IM injection of mRNA-1283 at Dose Level 2 on Day 1.

    Biological: mRNA-1283

  • Experimental
    Part A: mRNA-1283 Dose Level 3

    Participants will receive single IM injection of mRNA-1283 at Dose Level 3 on Day 1.

    Biological: mRNA-1283

  • Experimental
    Part A: mRNA-1283.211 Dose Level 1

    Participants will receive single IM injection of mRNA-1283.211 at Dose Level 1 on Day 1.

    Biological: mRNA-1283.211

  • Experimental
    Part A: mRNA-1283.211 Dose Level 2

    Participants will receive single IM injection of mRNA-1283.211 at Dose Level 2 on Day 1.

    Biological: mRNA-1283.211

  • Active comparator
    Part A: mRNA-1273

    Participants will receive single IM injection of mRNA-1273 on Day 1.

    Biological: mRNA-1273

  • Experimental
    Part B: mRNA-1283.529 Dose Level 1

    Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 1 on Day 1.

    Biological: mRNA-1283.529

  • Experimental
    Part B: mRNA-1283.529 Dose Level 2

    Participants will receive single IM injection of mRNA-1283.529 as a second booster at Dose Level 2 on Day 1.

    Biological: mRNA-1283.529

Interventions

  • BiologicalmRNA-1283

    Sterile liquid for injection

  • BiologicalmRNA-1283.211

    Sterile liquid for injection

  • BiologicalmRNA-1273

    Sterile liquid for injection

  • BiologicalmRNA-1283.529

    Sterile liquid for injection

07

What researchers measure

Primary outcomes

  1. Parts A and B: Number of Participants With Solicited Local and Solicited Systemic Reactogenicity Adverse Reactions (ARs)

    An AR is any adverse event (AE) related to the IP injection. Solicited local ARs included pain at injection site, erythema (redness) at injection site, swelling (hardness) at injection site, localized axillary swelling or tenderness ipsilateral to the injection arm, and groin or underarm swelling or tenderness ipsilateral to the side of injection. Solicited systemic ARs included headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, fever, chills, irritability/crying, sleepiness, and loss of appetite. Note, not all solicited ARs were considered AEs. The Investigator determined if solicited AR was also to be recorded as an AE. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to Day 7

  2. Parts A and B: Number of Participants With Unsolicited AEs

    An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Up to Day 28

  3. Parts A and B: Number of Participants With Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study Participation and AEs of Special Interest (AESIs)

    SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Day 1 to Day 366

  4. Part A: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Neutralizing Antibody (nAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

    The GMT (50% inhibitory dose \[ID50\]) of nAb against ancestral SARS-CoV-2 and against SARS-CoV-2 variant B.1.351 are reported.

    Time frame: Day 29

  5. Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

    The GMFR measures the changes in immunogenicity titers or levels within participants.

    Time frame: Day 29

  6. Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

    Seroresponse was defined as an increase of SARS-CoV-2 specific binding antibody (bAb) level or nAb titer to at least 4x lower limit of quantification (LLOQ) if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.

    Time frame: Day 29

  7. Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

    The GMT (ID50) of nAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.

    Time frame: Day 29

  8. Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

    The GMFR measures the changes in immunogenicity titers or levels within participants.

    Time frame: Day 29

  9. Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)

    Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.

    Time frame: Day 29

Secondary outcomes

  1. Part A: GMT of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

    The GMT (ID50) of nAb against ancestral SARS-CoV-2 and against SARS-CoV-2 Variant B.1.351 are reported.

    Time frame: Days 1, 29, 91, 181, and 366

  2. Part A: GMT of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

    The GMT of bAb against ancestral SARS-CoV-2 and against SARS-CoV-2 Variant B.1.351 are reported.

    Time frame: Days 1, 29, 91, 181, and 366

  3. Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

    The GMT (ID50) of nAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.

    Time frame: Days 1, 29, 91, 181, and 366

  4. Part B: GMT of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

    The GMT of bAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.

    Time frame: Days 1, 29, 91, 181, and 366

  5. Part A: GMFR of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

    The GMFR measures the changes in immunogenicity titers or levels within participants.

    Time frame: Days 29, 91, 181, and 366

  6. Part A: GMFR of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

    The GMFR measures the changes in immunogenicity titers or levels within participants.

    Time frame: Days 29, 91, 181, and 366

  7. Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

    The GMFR measures the changes in immunogenicity titers or levels within participants.

    Time frame: Days 29, 91, 181, and 366

  8. Part B: GMFR of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

    The GMFR measures the changes in immunogenicity titers or levels within participants.

    Time frame: Days 29, 91, 181, and 366

  9. Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

    Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.

    Time frame: Days 29, 91, 181, and 366

  10. Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)

    Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.

    Time frame: Days 29, 91, 181, and 366

Other outcomes

  1. Number of Deaths Related to Study Drug

    A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

    Time frame: Day 1 to Day 366

08

Results

Posted Jul 17, 2025

Participant flow

Part A
Participant flow — Part A
MilestonePart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Started57635653545700
Received at least 1 dose of study drug57635653545700
Completed51525449484700
Not completed6112461000
Withdrew: Other than specified10000000
Withdrew: Withdrawal by subject04113200
Withdrew: Lost to follow-up57133800
Part B
Participant flow — Part B
MilestonePart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Started00000010397
Received at least 1 dose of study drug00000010397
Completed0000009888
Not completed00000059
Withdrew: Withdrawal by subject00000002
Withdrew: Lost to follow-up00000055
Withdrew: Death00000002

Outcome measures

PrimaryParts A and B: Number of Participants With Solicited Local and Solicited Systemic Reactogenicity Adverse Reactions (ARs)

An AR is any adverse event (AE) related to the IP injection. Solicited local ARs included pain at injection site, erythema (redness) at injection site, swelling (hardness) at injection site, localized axillary swelling or tenderness ipsilateral to the injection arm, and groin or underarm swelling or tenderness ipsilateral to the side of injection. Solicited systemic ARs included headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, fever, chills, irritability/crying, sleepiness, and loss of appetite. Note, not all solicited ARs were considered AEs. The Investigator determined if solicited AR was also to be recorded as an AE. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to Day 7
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Solicited Local and Solicited Systemic Reactogenicity Adverse Reactions (ARs)
ParticipantsPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Solicited Local ARs3040372829464669
Solicited Systemic ARs3239353927415160
PrimaryParts A and B: Number of Participants With Unsolicited AEs

An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Unsolicited AEs
ParticipantsPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Parts A and B: Number of Participants With Unsolicited AEs1391112781311
PrimaryParts A and B: Number of Participants With Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study Participation and AEs of Special Interest (AESIs)

SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. MAAEs were AEs that lead to an unscheduled visit to a healthcare provider. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Day 1 to Day 366
Reported as:
Count of participants · Participants
Parts A and B: Number of Participants With Serious Adverse Events (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal From Study Participation and AEs of Special Interest (AESIs)
ParticipantsPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
SAEs21233226
MAAEs2523272418235142
AEs Leading to Withdrawal from Study Participation00000002
AESIs21000003
PrimaryPart A: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Neutralizing Antibody (nAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

The GMT (50% inhibitory dose \[ID50\]) of nAb against ancestral SARS-CoV-2 and against SARS-CoV-2 variant B.1.351 are reported.

Time frame:
Day 29
Reported as:
Geometric mean · Titer
Part A: Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Neutralizing Antibody (nAb) Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
TiterPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273
Ancestral SARS-CoV-2 ID504751.7 (3207.0 to 7040.5)5666.5 (4149.3 to 7738.4)7723.0 (5621.7 to 10609.7)5105.5 (3083.3 to 8453.9)4729.8 (2572.4 to 8696.3)3562.9 (2550.1 to 4977.9)
SARS-CoV-2 Variant B.1.351 ID50946.7 (611.4 to 1465.7)1216.2 (838.9 to 1763.3)2020.1 (1350.7 to 3021.1)1566.3 (942.4 to 2603.2)1224.8 (660.6 to 2271.0)964.4 (659.6 to 1410.1)
PrimaryPart A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

The GMFR measures the changes in immunogenicity titers or levels within participants.

Time frame:
Day 29
Reported as:
Geometric mean · Ratio
Part A: Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
RatioPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273
Ancestral SARS-CoV-2 ID5026.8 (16.8 to 42.8)34.3 (20.9 to 56.0)45.3 (27.0 to 76.0)35.5 (18.1 to 69.6)28.1 (13.2 to 59.9)24.5 (14.7 to 40.7)
SARS-CoV-2 Variant B.1.351 ID5027.4 (16.2 to 46.6)33.7 (21.1 to 53.9)52.1 (30.2 to 89.8)54.2 (27.2 to 107.7)41.8 (20.8 to 84.0)35.8 (19.8 to 64.6)
PrimaryPart A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

Seroresponse was defined as an increase of SARS-CoV-2 specific binding antibody (bAb) level or nAb titer to at least 4x lower limit of quantification (LLOQ) if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
ParticipantsPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273
Ancestral SARS-CoV-2 ID50283530221926
SARS-CoV-2 Variant B.1.351 ID50263531221925
PrimaryPart B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

The GMT (ID50) of nAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.

Time frame:
Day 29
Reported as:
Geometric mean · Titer
Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
TiterPart B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)1562.9 (1113.4 to 2194.0)2723.0 (1938.3 to 3825.4)
PrimaryPart B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

The GMFR measures the changes in immunogenicity titers or levels within participants.

Time frame:
Day 29
Reported as:
Geometric mean · Ratio
Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
RatioPart B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)7.2 (5.7 to 9.0)7.8 (5.9 to 10.4)
PrimaryPart B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)

Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.

Time frame:
Day 29
Reported as:
Count of participants · Participants
Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)
ParticipantsPart B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)5548
SecondaryPart A: GMT of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

The GMT (ID50) of nAb against ancestral SARS-CoV-2 and against SARS-CoV-2 Variant B.1.351 are reported.

Time frame:
Days 1, 29, 91, 181, and 366
Reported as:
Geometric mean · Titer
Part A: GMT of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
TiterPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273
Day 1 Ancestral SARS-CoV-2 ID50177.4 (108.5 to 290.0)165.4 (114.4 to 239.2)170.4 (104.4 to 278.0)143.7 (97.0 to 213.1)168.6 (74.5 to 381.3)145.6 (91.9 to 230.7)
Day 29 Ancestral SARS-CoV-2 ID504751.7 (3207.0 to 7040.5)5666.5 (4149.3 to 7738.4)7723.0 (5621.7 to 10609.7)5105.5 (3083.3 to 8453.9)4729.8 (2572.4 to 8696.3)3562.9 (2550.1 to 4977.9)
Day 91 Ancestral SARS-CoV-2 ID503980.4 (2459.2 to 6442.6)4589.2 (3285.9 to 6409.4)6754.5 (4604.3 to 9909.0)4943.1 (3029.0 to 8066.9)4319.8 (2758.9 to 6763.7)3155.1 (1980.2 to 5027.0)
Day 181 Ancestral SARS-CoV-2 ID502476.4 (1400.5 to 4378.8)2861.4 (1879.2 to 4357.1)3834.7 (2606.2 to 5642.2)2960.3 (1805.5 to 4853.6)2767.2 (1588.2 to 4821.6)1269.4 (809.8 to 1990.0)
Day 366 Ancestral SARS-CoV-2 ID501497.4 (723.2 to 3100.5)3097.6 (2003.1 to 4790.2)2921.1 (2062.2 to 4137.8)2013.3 (1225.1 to 3308.5)1539.6 (772.8 to 3067.3)1336.1 (739.4 to 2414.2)
Day 1 SARS-CoV-2 Variant B.1.351 ID5034.5 (21.0 to 56.5)36.1 (25.9 to 50.3)38.8 (24.0 to 62.6)28.9 (19.0 to 44.0)29.3 (14.2 to 60.4)27.9 (17.5 to 44.6)
Day 29 SARS-CoV-2 Variant B.1.351 ID50946.7 (611.4 to 1465.7)1216.2 (838.9 to 1763.3)2020.1 (1350.7 to 3021.1)1566.3 (942.4 to 2603.2)1224.8 (660.6 to 2271.0)964.4 (659.6 to 1410.1)
Day 91 SARS-CoV-2 Variant B.1.351 ID50794.8 (461.9 to 1367.5)965.6 (631.0 to 1477.7)1520.8 (1025.7 to 2254.8)1105.8 (579.9 to 2108.6)990.5 (591.0 to 1660.0)640.2 (384.2 to 1066.7)
Day 181 SARS-CoV-2 Variant B.1.351 ID50786.3 (403.1 to 1533.7)760.2 (438.7 to 1317.2)1458.4 (916.6 to 2320.5)967.2 (531.3 to 1760.7)769.6 (429.6 to 1378.9)460.5 (266.1 to 796.9)
Day 366 SARS-CoV-2 Variant B.1.351 ID50581.2 (279.7 to 1207.6)1461.8 (855.0 to 2499.1)1259.6 (789.7 to 2009.1)790.3 (397.0 to 1573.3)530.3 (223.4 to 1258.4)534.2 (252.1 to 1132.1)
SecondaryPart A: GMT of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

The GMT of bAb against ancestral SARS-CoV-2 and against SARS-CoV-2 Variant B.1.351 are reported.

Time frame:
Days 1, 29, 91, 181, and 366
Reported as:
Geometric mean · Titer
Part A: GMT of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
TiterPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273
Day 1 Ancestral SARS-CoV-229458.4 (18988.8 to 45700.5)29839.6 (21775.9 to 40889.2)32632.4 (22347.8 to 47650.0)28886.5 (21389.0 to 39012.1)30803.7 (17375.8 to 54608.8)30644.3 (21431.7 to 43817.0)
Day 29 Ancestral SARS-CoV-2717040.9 (545647.9 to 942269.9)737925.6 (580477.3 to 938080.1)1070144.5 (823120.1 to 1391302.9)835783.7 (570117.5 to 1225246.2)688909.2 (429957.5 to 1103820.5)594926.9 (462362.9 to 765498.3)
Day 91 Ancestral SARS-CoV-2538518.6 (370446.8 to 782844.8)575062.5 (432778.8 to 764124.4)785822.0 (601645.3 to 1026379.3)613915.9 (398665.6 to 945385.7)629867.6 (446549.5 to 888441.8)390985.5 (289339.3 to 528340.5)
Day 181 Ancestral SARS-CoV-2349027.0 (227163.4 to 536265.3)338163.9 (239965.4 to 476547.2)447634.3 (336503.1 to 595467.0)370694.6 (257195.7 to 534280.0)358399.9 (238972.0 to 537512.6)198042.8 (141579.1 to 277025.1)
Day 366 Ancestral SARS-CoV-2220315.4 (125437.1 to 386957.9)390137.4 (266323.9 to 571511.7)370475.8 (277402.5 to 494776.9)260942.1 (185711.7 to 366647.8)246749.8 (150746.4 to 403893.4)163960.1 (107650.0 to 249725.1)
Day 1 SARS-CoV-2 Variant B.1.35112499.8 (8275.5 to 18880.3)13289.6 (9765.0 to 18086.4)15875.3 (10891.6 to 23139.3)15255.0 (10255.8 to 22691.2)12664.6 (7792.9 to 20581.8)17401.8 (11236.5 to 26950.0)
Day 29 SARS-CoV-2 Variant B.1.351359208.1 (259502.7 to 497221.9)369055.6 (277237.5 to 491282.7)504673.7 (387088.6 to 657977.5)399270.2 (261474.1 to 609684.5)352867.0 (193718.3 to 642763.9)333866.2 (264529.3 to 421377.3)
Day 91 SARS-CoV-2 Variant B.1.351237940.9 (154308.2 to 366901.3)271701.9 (194943.5 to 378683.7)362689.3 (275141.6 to 478093.9)245501.5 (154897.5 to 389102.6)330103.6 (246861.3 to 441415.5)202152.0 (158047.0 to 258564.9)
Day 181 SARS-CoV-2 Variant B.1.351151202.9 (90854.0 to 251638.2)143620.7 (94068.8 to 219274.8)184376.3 (134452.0 to 252838.3)142996.2 (92494.0 to 221072.9)183952.8 (130226.4 to 259844.8)95496.2 (70938.4 to 128555.5)
Day 366 SARS-CoV-2 Variant B.1.351105204.5 (53545.8 to 206701.3)218574.3 (128094.7 to 372964.0)203600.7 (133854.9 to 309687.7)121911.8 (68950.3 to 215553.6)134120.4 (70688.7 to 254471.9)89012.3 (53840.6 to 147160.1)
SecondaryPart B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

The GMT (ID50) of nAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.

Time frame:
Days 1, 29, 91, 181, and 366
Reported as:
Geometric mean · Titer
Part B: GMT of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
TiterPart B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Day 1 SARS-CoV-2 Variant B.1.1.529 ID50217.6 (162.0 to 292.4)349.2 (239.7 to 508.7)
Day 29 SARS-CoV-2 Variant B.1.1.529 ID501562.9 (1113.4 to 2194.0)2723.0 (1938.3 to 3825.4)
Day 91 SARS-CoV-2 Variant B.1.1.529 ID50978.5 (667.7 to 1434.0)1713.5 (1238.2 to 2371.4)
Day 181 SARS-CoV-2 Variant B.1.1.529 ID50724.0 (500.9 to 1046.5)1608.7 (1053.9 to 2455.5)
Day 366 SARS-CoV-2 Variant B.1.1.529 ID50666.0 (395.5 to 1121.8)1873.7 (1156.9 to 3034.9)
SecondaryPart B: GMT of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

The GMT of bAb against SARS-CoV-2 omicron variant (B.1.1.529) are reported.

Time frame:
Days 1, 29, 91, 181, and 366
Reported as:
Geometric mean · Titer
Part B: GMT of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
TiterPart B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Day 1 SARS-CoV-2 Variant B.1.1.52950830.3 (41890.8 to 61677.5)61419.3 (49407.6 to 76351.2)
Day 29 SARS-CoV-2 Variant B.1.1.529182046.9 (153016.2 to 216585.4)233677.5 (189382.6 to 288332.8)
Day 91 SARS-CoV-2 Variant B.1.1.529118658.1 (97721.5 to 144080.3)157262.3 (126717.0 to 195170.7)
Day 181 SARS-CoV-2 Variant B.1.1.52973469.5 (58947.0 to 91569.8)103322.9 (81221.9 to 131437.7)
Day 366 SARS-CoV-2 Variant B.1.1.52946721.5 (32757.5 to 66638.1)98989.7 (67965.4 to 144175.8)
SecondaryPart A: GMFR of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

The GMFR measures the changes in immunogenicity titers or levels within participants.

Time frame:
Days 29, 91, 181, and 366
Reported as:
Geometric mean · Ratio
Part A: GMFR of SARS-CoV-2 Specific nAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
RatioPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273
Day 29 Ancestral SARS-CoV-2 ID5026.8 (16.8 to 42.8)34.3 (20.9 to 56.0)45.3 (27.0 to 76.0)35.5 (18.1 to 69.6)28.1 (13.2 to 59.9)24.5 (14.7 to 40.7)
Day 91 Ancestral SARS-CoV-2 ID5022.4 (13.5 to 37.4)27.1 (16.5 to 44.6)39.6 (23.0 to 68.3)34.0 (17.2 to 67.1)25.6 (12.2 to 53.9)21.7 (12.4 to 38.0)
Day 181 Ancestral SARS-CoV-2 ID5013.9 (7.4 to 26.0)17.1 (9.9 to 29.7)23.6 (13.2 to 42.1)20.6 (11.1 to 38.2)15.3 (7.6 to 30.7)8.2 (4.6 to 14.6)
Day 366 Ancestral SARS-CoV-2 ID509.1 (4.3 to 19.2)18.0 (9.5 to 33.9)17.8 (10.3 to 30.6)13.7 (7.1 to 26.4)9.8 (4.1 to 23.3)8.7 (4.3 to 17.6)
Day 29 SARS-CoV-2 Variant B.1.351 ID5027.4 (16.2 to 46.6)33.7 (21.1 to 53.9)52.1 (30.2 to 89.8)54.2 (27.2 to 107.7)41.8 (20.8 to 84.0)35.8 (19.8 to 64.6)
Day 91 SARS-CoV-2 Variant B.1.351 ID5023.0 (12.8 to 41.6)27.0 (16.5 to 44.4)39.2 (21.9 to 70.3)38.1 (16.9 to 85.9)33.8 (17.7 to 64.6)23.9 (12.7 to 45.3)
Day 181 SARS-CoV-2 Variant B.1.351 ID5021.4 (10.1 to 45.1)21.4 (12.3 to 37.2)39.3 (21.0 to 73.4)33.4 (15.8 to 70.6)24.9 (12.6 to 49.4)16.5 (8.3 to 32.8)
Day 366 SARS-CoV-2 Variant B.1.351 ID5017.6 (8.0 to 38.7)38.2 (20.0 to 73.2)32.5 (17.6 to 59.7)27.4 (12.3 to 61.0)20.0 (7.9 to 50.4)18.9 (8.0 to 44.7)
SecondaryPart A: GMFR of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

The GMFR measures the changes in immunogenicity titers or levels within participants.

Time frame:
Days 29, 91, 181, and 366
Reported as:
Geometric mean · Ratio
Part A: GMFR of SARS-CoV-2 Specific bAb Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
RatioPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273
Day 29 Ancestral SARS-CoV-224.3 (16.1 to 36.9)24.7 (16.2 to 37.7)32.8 (21.4 to 50.2)28.9 (16.2 to 51.6)22.4 (12.1 to 41.4)19.8 (12.4 to 31.4)
Day 91 Ancestral SARS-CoV-217.5 (11.3 to 27.2)19.0 (12.1 to 29.8)24.1 (15.6 to 37.3)20.9 (11.3 to 38.5)20.4 (12.2 to 34.3)12.8 (8.2 to 20.0)
Day 181 Ancestral SARS-CoV-211.5 (7.1 to 18.7)11.2 (6.9 to 18.2)14.0 (8.8 to 22.3)12.8 (7.6 to 21.8)11.6 (6.8 to 20.0)6.2 (3.9 to 9.9)
Day 366 Ancestral SARS-CoV-28.5 (4.8 to 15.0)12.9 (7.5 to 22.1)11.4 (7.4 to 17.5)8.8 (5.3 to 14.8)8.5 (4.5 to 16.1)5.3 (3.0 to 9.4)
Day 29 SARS-CoV-2 Variant B.1.35128.7 (18.9 to 43.8)27.8 (17.6 to 43.8)31.8 (20.3 to 49.8)26.2 (14.1 to 48.7)27.9 (13.1 to 59.4)19.8 (12.0 to 32.7)
Day 91 SARS-CoV-2 Variant B.1.35118.1 (11.4 to 28.7)20.5 (12.7 to 33.1)22.8 (14.0 to 37.4)15.9 (8.1 to 31.0)26.1 (15.1 to 45.0)11.7 (7.5 to 18.3)
Day 181 SARS-CoV-2 Variant B.1.35111.5 (6.8 to 19.6)10.8 (6.3 to 18.4)11.9 (7.1 to 20.0)9.4 (5.2 to 17.0)15.0 (8.5 to 26.6)5.1 (3.2 to 8.2)
Day 366 SARS-CoV-2 Variant B.1.3518.3 (4.4 to 16.0)17.1 (9.4 to 31.1)12.9 (7.6 to 21.7)7.7 (3.4 to 17.5)12.4 (6.0 to 25.5)5.2 (2.7 to 9.8)
SecondaryPart B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

The GMFR measures the changes in immunogenicity titers or levels within participants.

Time frame:
Days 29, 91, 181, and 366
Reported as:
Geometric mean · Ratio
Part B: GMFR of SARS-CoV-2 Specific nAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
RatioPart B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Day 29 SARS-CoV-2 Variant B.1.1.529 ID507.2 (5.7 to 9.0)7.8 (5.9 to 10.4)
Day 91 SARS-CoV-2 Variant B.1.1.529 ID504.6 (3.3 to 6.3)5.0 (3.6 to 6.8)
Day 181 SARS-CoV-2 Variant B.1.1.529 ID503.4 (2.3 to 5.0)4.5 (2.8 to 7.3)
Day 366 SARS-CoV-2 Variant B.1.1.529 ID502.5 (1.5 to 4.3)6.4 (3.3 to 12.6)
SecondaryPart B: GMFR of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)

The GMFR measures the changes in immunogenicity titers or levels within participants.

Time frame:
Days 29, 91, 181, and 366
Reported as:
Geometric mean · Ratio
Part B: GMFR of SARS-CoV-2 Specific bAb Against SARS-CoV-2 Omicron Variant (B.1.1.529)
RatioPart B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Day 293.6 (3.0 to 4.3)3.8 (3.2 to 4.5)
Day 912.3 (1.9 to 2.8)2.5 (2.0 to 3.0)
Day 1811.5 (1.2 to 1.8)1.6 (1.3 to 2.0)
Day 3660.9 (0.6 to 1.2)1.7 (1.1 to 2.6)
SecondaryPart A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351

Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.

Time frame:
Days 29, 91, 181, and 366
Reported as:
Count of participants · Participants
Part A: Number of Participants With Seroresponse Against Ancestral SARS-CoV-2 and Against SARS-CoV-2 Variant B.1.351
ParticipantsPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273
Day 29 Ancestral SARS-CoV-2 ID50283530221926
Day 91 Ancestral SARS-CoV-2 ID50273229201926
Day 181 Ancestral SARS-CoV-2 ID50242927191717
Day 366 Ancestral SARS-CoV-2 ID50182527181214
Day 29 SARS-CoV-2 Variant B.1.351 ID50263531221925
Day 91 SARS-CoV-2 Variant B.1.351 ID50263329202024
Day 181 SARS-CoV-2 Variant B.1.351 ID50233028221720
Day 366 SARS-CoV-2 Variant B.1.351 ID50172728171416
SecondaryPart B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)

Seroresponse was defined as an increase of SARS-CoV-2 specific bAb level or nAb titer to at least 4x LLOQ if the baseline is below the LLOQ, or a 4-fold or greater rise if pre-booster ≥ LLOQ.

Time frame:
Days 29, 91, 181, and 366
Reported as:
Count of participants · Participants
Part B: Number of Participants With Seroresponse Against SARS-CoV-2 Omicron Variant (B.1.1.529)
ParticipantsPart B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Day 29 ID505548
Day 91 ID503235
Day 181 ID502628
Day 366 ID502024
Other pre-specifiedNumber of Deaths Related to Study Drug

A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.

Time frame:
Day 1 to Day 366
Reported as:
Count of participants · Participants
Number of Deaths Related to Study Drug
ParticipantsPart A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High Dose
Deaths00000002
Deaths related to study drug00000000

Adverse events

Collected over Day 1 to Day 366. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: mRNA-1283 2.5ug Booster0/57 (0%)2/57 (3.5%)15/57 (26.3%)
Part A: mRNA-1283 5ug Booster0/64 (0%)1/64 (1.6%)13/64 (20.3%)
Part A: mRNA-1283 10ug Booster0/56 (0%)2/56 (3.6%)16/56 (28.6%)
Part A: mRNA-1283.211 5ug Booster0/52 (0%)3/52 (5.8%)18/52 (34.6%)
Part A: mRNA-1283.211 10ug Booster0/54 (0%)3/54 (5.6%)12/54 (22.2%)
Part A: mRNA-1273 50ug Booster0/57 (0%)2/57 (3.5%)16/57 (28.1%)
Part B: mRNA-1283.529 5ug Booster0/103 (0%)2/103 (1.9%)24/103 (23.3%)
Part B: mRNA-1283.529 10ug Booster2/97 (2.1%)6/97 (6.2%)24/97 (24.7%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventPart A: mRNA-1283 2.5ug BoosterPart A: mRNA-1283 5ug BoosterPart A: mRNA-1283 10ug BoosterPart A: mRNA-1283.211 5ug BoosterPart A: mRNA-1283.211 10ug BoosterPart A: mRNA-1273 50ug BoosterPart B: mRNA-1283.529 5ug BoosterPart B: mRNA-1283.529 10ug Booster
Herpes zosterInfections and infestations0/570/640/561/521/540/570/1030/97
Breast cancer stage INeoplasms benign, malignant and unspecified (incl cysts and polyps)0/570/640/561/520/540/570/1030/97
HyperglycaemiaMetabolism and nutrition disorders0/570/640/561/520/540/570/1030/97
Cerebrospinal fluid leakageNervous system disorders0/570/640/561/520/540/570/1030/97
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/570/640/561/520/540/570/1030/97
Staphylococcal infectionInfections and infestations0/570/640/560/521/540/570/1030/97
Small intestine carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/570/640/560/521/540/570/1030/97
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/570/641/560/520/540/570/1030/97
Small intestinal obstructionGastrointestinal disorders0/570/641/560/520/540/570/1030/97
AppendicitisInfections and infestations1/570/640/560/520/540/570/1031/97
Most frequent other events
Most frequent other events
EventPart A: mRNA-1283 2.5ug BoosterPart A: mRNA-1283 5ug BoosterPart A: mRNA-1283 10ug BoosterPart A: mRNA-1283.211 5ug BoosterPart A: mRNA-1283.211 10ug BoosterPart A: mRNA-1273 50ug BoosterPart B: mRNA-1283.529 5ug BoosterPart B: mRNA-1283.529 10ug Booster
Upper respiratory tract infectionInfections and infestations7/578/648/565/526/546/5714/10317/97
HypertensionVascular disorders4/571/642/561/520/540/575/1034/97
NasopharyngitisInfections and infestations1/571/642/563/522/541/570/1033/97
ArthralgiaMusculoskeletal and connective tissue disorders2/570/641/563/521/541/572/1032/97
Back painMusculoskeletal and connective tissue disorders0/570/640/563/521/542/572/1032/97
Influenza like illnessGeneral disorders0/571/641/563/521/540/570/1030/97
InfluenzaInfections and infestations3/571/641/561/521/541/570/1034/97
Respiratory tract infection viralInfections and infestations1/570/641/561/520/543/571/1032/97
AnxietyPsychiatric disorders0/572/641/561/520/543/573/1032/97
Irritable bowel syndromeGastrointestinal disorders0/570/640/560/520/543/570/1030/97

Baseline characteristics

Measured in the Safety Set, which consisted of all randomized/enrolled (Part A: randomized, Part B: enrolled) participants who received one dose of investigational product (IP). Data in the Safety Set is presented per actual dose received. There was 1 participant in the mRNA-1283.211 low dose group who had a dosing error and received mRNA-1283 at medium dose.

Age, Customized
Age, Customized(Participants)Part A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High DoseTotal
>=18 and <56 Years4046423740424459350
>=56 Years1718141514155938190
Sex: Female, Male
Sex: Female, Male(Participants)Part A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High DoseTotal
Female3143323439327062343
Male2621241815253335197
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High DoseTotal
Hispanic or Latino1014898112466
Not Hispanic or Latino47504743434510093468
Unknown or Not Reported001031106
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: mRNA-1283 Low DosePart A: mRNA-1283 Medium DosePart A: mRNA-1283 High DosePart A: mRNA-1283.211 Low DosePart A: mRNA-1283.211 High DosePart A: mRNA-1273Part B: mRNA-1283.529 Low DosePart B: mRNA-1283.529 High DoseTotal
American Indian or Alaska Native000020103
Asian5133330220
Native Hawaiian or Other Pacific Islander000000101
Black or African American1111991067770
White4148413837479488434
More than one race021111006
Unknown or Not Reported022110006
09

Study locations

17 sites
  • MedPharmics, LLC
    Phoenix, Arizona 85015-1105, United States
  • Research Centers of America
    Hollywood, Florida 33024-2709, United States
  • Precision Clinical Research
    Sunrise, Florida 33351-7311, United States
  • Tekton Research
    Chamblee, Georgia 30341, United States
  • MedPharmics
    Metairie, Louisiana 70006, United States
  • UMass Memorial Medical Center
    Worcester, Massachusetts 01655-0002, United States
  • Clinical Research Institute, Inc - CRN
    Minneapolis, Minnesota 55402-2700, United States
  • Meridian Clinical Research (Nebraska)
    Lincoln, Nebraska 68510, United States
  • MedPharmics, LLC. - Albuquerque
    Albuquerque, New Mexico 87102-3876, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Meridian Clinical Research (Cincinnati)
    Cincinnati, Ohio 45246-2316, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213-6517, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405-4986, United States
  • ACRC Trials
    Frisco, Texas 75033-4135, United States
  • Ventavia Research Group
    Houston, Texas 77008, United States
  • Health Research of Hampton Roads Inc.
    Newport News, Virginia 23606-4537, United States
10

References and documents

Publications

  • Chalkias S, Pragalos A, Akinsola A, Berman G, Ampajwala M, Meyer J, Schoch L, Zhou W, Paila YD, Deng W, Feng J, de Windt E, Edwards D, Miller J, Das R. Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA Vaccine. J Infect Dis. 2025 Apr 15;231(4):e754-e763. doi: 10.1093/infdis/jiaf022. PubMed 39792478 ↗
  • Stewart-Jones GBE, Elbashir SM, Wu K, Lee D, Renzi I, Ying B, Koch M, Sein CE, Choi A, Whitener B, Garcia-Dominguez D, Henry C, Woods A, Ma L, Montes Berrueta D, Avena LE, Quinones J, Falcone S, Hsiao CJ, Scheaffer SM, Thackray LB, White P, Diamond MS, Edwards DK, Carfi A. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. Sci Transl Med. 2023 Sep 13;15(713):eadf4100. doi: 10.1126/scitranslmed.adf4100. Epub 2023 Sep 13. PubMed 37703353 ↗
  • Stewart-Jones GBE, Elbashir SM, Wu K, Lee D, Renzi I, Ying B, Koch M, Sein CE, Choi A, Whitener B, Garcia-Dominguez D, Henry C, Woods A, Ma L, Montes Berrueta D, Avena LE, Quinones J, Falcone S, Hsiao CJ, Scheaffer SM, Thackray LB, White P, Diamond MS, Edwards DK, Carfi A. Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains. bioRxiv [Preprint]. 2022 Oct 7:2022.10.07.511319. doi: 10.1101/2022.10.07.511319. PubMed 36238717 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Mar 2023, 15 months.

Results were first posted in Jul 2025, 2 years 3 months after primary completion. A results delay was requested in Mar 2024.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 15 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2021
First posted
Nov 30, 2021
StartActual
Dec 6, 2021
Primary completionActual
Mar 23, 2023
CompletionActual
Mar 23, 2023
Results delay requested
Mar 19, 2024
Results first posted
Jul 17, 2025
Last update
Jul 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05137236
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Nov 30, 2021
Start date
Dec 6, 2021
Primary completion
Mar 23, 2023
Completion
Mar 23, 2023
Results posted
Jul 17, 2025
Last update
Jul 17, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MRNA-1283

Start the discussion